Masimo announces expanded partnership with Shenzhen Mindray for SET®
Category: #health  By Pankaj Singh  Date: 2019-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Masimo announces expanded partnership with Shenzhen Mindray for SET®

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion.

The U.S. based medical device manufacturing company Masimo has reportedly announced that it has signed a purchase and license agreement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to leverage Mindray’s SET® Measure-through Motion and Low Perfusion™ pulse oximetry – noninvasive, incessant measurement of oxygen saturation (SpO2), perfusion index (Pi), and pulse rate (PR),  – in monitoring devices.

Reportedly, the devices by Mindray which are equipped with SET® will be now available in select countries in the Middle East, Europe, the Commonwealth of Independent States, Asia-Pacific (excluding China), including Australia, India, and Russia.

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion. SET® has presented the highest sensitivity and specificity in detecting desaturation events and preventing false desaturation events during these conditions in a study which compared multiple pulse oximetry technologies.

SET® has reportedly launched latest frontiers in monitoring of patients during challenging conditions: outcome studies have shown that SET®, aided with clinical assessment, has facilitated clinicians to reduce retinopathy of prematurity (ROP) in neonates, improve critical congenital heart disease (CCHD) screening in infants, and reduce ICU transfers and rapid response team activations by continuously monitoring patients in post-surgical wards. Among all the studies, more than 100 independent and objective studies have demonstrated that SET® surpasses other pulse oximetry technologies. Masimo has continuously improved SET®, and recently announced that SpO2 precision specifications have now enhanced to 1.5 percent in conditions of motion and no motion for adult, pediatric, and newborn patients, weighing less than 3 kg, with RD SET™ sensors. 

The advantages of Masimo SET® are now available to clinicians leveraging devices of Mindray in several countries outside the U.S., where Mindray has provided SET® pulse oximetry in devices from Datascope since acquiring it in the year 2008.

Source credit: https://www.biospace.com/article/releases/masimo-and-mindray-announce-expanded-partnership/

http://www.masimo.com/company/news/news-media/#news-05b424de-a21b-4533-99c5-13f5ae2d3ed6



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...